BioVersys AG Cash Flow Statement

Financials in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-19.36	-18.72	-18.3
Depreciation & Amortization	0.28	0.28	0.27
Loss (Gain) From Sale of Investments	-0.43	-0.43	0.21
Stock-Based Compensation	0.46	1.86	1.72
Other Operating Activities	2.29	0.88	0.72
Change in Accounts Payable	-0.99	-2.8	4.8
Change in Other Net Operating Assets	1.08	3.36	-1.08
Operating Cash Flow	-16.67	-15.57	-11.66
Capital Expenditures	-0.04	-0.04	-0.05
Investment in Securities	11	-2	3.34
Investing Cash Flow	10.96	-2.04	3.29
Long-Term Debt Issued	-	-	7.38
Long-Term Debt Repaid	-	-0.25	-0.25
Net Debt Issued (Repaid)	-0.25	-0.25	7.13
Issuance of Common Stock	76.84	14.71	0.02
Other Financing Activities	-1.71	4.73	-0.02
Financing Cash Flow	74.88	19.19	7.13
Foreign Exchange Rate Adjustments	-0.68	0.66	-0.95
Net Cash Flow	68.49	2.24	-2.19
Free Cash Flow	-16.71	-15.61	-11.7
Free Cash Flow Margin	-1276.39%	-1287.06%	-1027.57%
Free Cash Flow Per Share	-3.75	-4.68	-3.92
Cash Interest Paid	0.06	0.08	0.02
Levered Free Cash Flow	-	-9.46	-
Unlevered Free Cash Flow	-	-8.82	-
Change in Working Capital	0.09	0.56	3.72

Source: S&P Global Market Intelligence. Standard template. Financial Sources.